ClinicalTrials.gg
RecruitingNCT05018819Updated Nov 18, 2026

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP

A Phase 1 interventional study of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells in Cerebral Palsy, sponsored by The Foundation for Orthopaedics and Regenerative Medicine. Recruiting at 2 sites in 2 countries. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by The Foundation for Orthopaedics and Regenerative Medicine · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.
Updated Nov 18, 2026First site in United StatesNo longer in Antigua and Barbuda+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 372 studies in Cerebral Palsy with a site in United States — 74 open to participants now, 102 under way, none of them phase 3. Cerebral Palsy · United States.

Planned enrollment
192nd of 296
15 · median 25
Started
2022
with 24 others
Phase 1
25 of 372
4 open now
Primary completion
2027-11
later than 57 of 101 live
Registered
237th of 372
by date

Among the 372 studies in Cerebral Palsy with a site in United States, this one is the 192nd largest by planned enrollment of the 296 interventional ones that give a count, is one of 25 that started in 2022, is one of 25 in phase 1, reaches primary completion later than 57 of the 101 other live ones, and was the 237th registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

74 of the 372 studies in Cerebral Palsy with a site in United States are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 372 studies in Cerebral Palsy with a site in United States, or all of them as a file.
02

Study summary

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells for the treatment of Cerebral Palsy

Read the detailed description

Studies have shown that stem cell treatment is safe and efficacious for the treatment of Cerebral Palsy (CP). This patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (MSCs) for the treatment of CP. Patients with CP will receive a single intravenous infusion of MSCs. Patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

03

Conditions studied

  • Cerebral Palsy

Browse trials for

Keywords

  • Cerebral Palsy
  • CP
  • stem cell treatment
04

Who can participate

The criteria were revised on the registry on Nov 18, 2026. See what changed

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Cerebral Palsy
  • Minimum Age: 5 years
  • Minimum Weight: 20 kg

Exclusion criteria

Exclusion Criteria:

  • Active infection
  • Active cancer
  • Chronic multisystem organ failure
  • Pregnancy
  • Abnormalities on pre-treatment laboratory evaluation
  • Medical condition that would (based on the opinion of the investigator) compromise patient's safety
  • Previous organ transplant
  • Seizure disorder
  • to sulfur
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Treatment Group

    Single intravenous infusion

    Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

Interventions

  • Biologicalcultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

    cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells

06

What researchers measure

Primary outcomes

  1. Safety (adverse events)

    Clinical monitoring of possible adverse events or complications

    Time frame: Four year follow-up

Secondary outcomes

  1. Efficacy: Gross Motor Function Measure (GMFM)

    It will be completed for each follow up point

    Time frame: Four year follow-up

07

Study locations

2 of 2 sites recruiting
08

References and documents

Publications

  • Alotaibi M, Long T, Kennedy E, Bavishi S. The efficacy of GMFM-88 and GMFM-66 to detect changes in gross motor function in children with cerebral palsy (CP): a literature review. Disabil Rehabil. 2014;36(8):617-27. doi: 10.3109/09638288.2013.805820. Epub 2013 Jun 26. PubMed 23802141 ↗
  • Ko J, Kim M. Reliability and responsiveness of the gross motor function measure-88 in children with cerebral palsy. Phys Ther. 2013 Mar;93(3):393-400. doi: 10.2522/ptj.20110374. Epub 2012 Nov 8. PubMed 23139425 ↗
  • Huang L, Zhang C, Gu J, Wu W, Shen Z, Zhou X, Lu H. A Randomized, Placebo-Controlled Trial of Human Umbilical Cord Blood Mesenchymal Stem Cell Infusion for Children With Cerebral Palsy. Cell Transplant. 2018 Feb;27(2):325-334. doi: 10.1177/0963689717729379. PubMed 29637820 ↗
  • Min K, Song J, Kang JY, Ko J, Ryu JS, Kang MS, Jang SJ, Kim SH, Oh D, Kim MK, Kim SS, Kim M. Umbilical cord blood therapy potentiated with erythropoietin for children with cerebral palsy: a double-blind, randomized, placebo-controlled trial. Stem Cells. 2013 Mar;31(3):581-91. doi: 10.1002/stem.1304. PubMed 23281216 ↗
09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Nov 2027, 69 months after the start.

Of 22 phase 1 interventional studies under Cerebral Palsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 43. This study's planned 69 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2021
First posted
Aug 24, 2021
StartActual
Feb 1, 2022
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed — first site in United States; no longer in Antigua and Barbuda
Show 2 added (1 United States, 1 Greece)
  • Prodromos Stem Cell Institute · Naples, United States
  • Prodromos Stem Cell Institute · Athens, Greece
Show 2 removed
  • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
  • Athens Beverly Hills Medical Group · Glyfáda, Greece
Oct 20, 2026
Eligibility
Minimum age none→5 Years; 2 inclusion criteria added
What changed in the criteria
Inclusion criteria
  • AddedMinimum Age: 5 years
  • AddedMinimum Weight: 20 kg
Nov 18, 2026
Interventions
Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; removed Biological: AlloRx
Oct 20, 2026
Title
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP
Oct 20, 2026
Show all 2 updates
  1. Nov 18, 2026
    Eligibility Minimum age none→5 Years; 2 inclusion criteria added
    What changed in the criteria
    Inclusion criteria
    • AddedMinimum Age: 5 years
    • AddedMinimum Weight: 20 kg
    + 1 other change: verification date
  2. Oct 20, 2026
    2 sites added, 2 sites removed — first site in United States; no longer in Antigua and Barbuda
    Show 2 added (1 United States, 1 Greece)
    • Prodromos Stem Cell Institute · Naples, United States
    • Prodromos Stem Cell Institute · Athens, Greece
    Show 2 removed
    • Medical Surgical Associates Center · St. John's, Antigua and Barbuda
    • Athens Beverly Hills Medical Group · Glyfáda, Greece
    Interventions Added Biological: cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells; removed Biological: AlloRx
    Title Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP
    + 3 other changes: verification date, description and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05018819
Lead sponsor
The Foundation for Orthopaedics and Regenerative Medicine
Responsible party
Sponsor
First posted
Aug 24, 2021
Start date
Feb 1, 2022
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Chadwick Prodromos, MD
principal investigator · The Foundation for Orthopaedics and Regenerative Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion